MDMAMDPV is a novel synthetic research compound that merges structural features of MDMA (a widely studied empathogen) and MDPV (a potent stimulant cathinone). It is chemically designed to offer researchers a dual-action profile with stimulant and entactogenic effects, which are rarely seen in one compound. Unlike single-class compounds, MDMAMDPV is capable of influencing both the serotonin and dopamine systems, making it valuable in comparative neurochemical studies.

• Hybrid Structure: MDMAMDPV contains the methylenedioxyphenyl ring from MDMA and the extended side chain associated with MDPV, making it structurally and functionally distinct from either parent compound.

• Dual Neurochemical Activity: It is thought to affect both the dopamine transporter (like MDPV) and the serotonin transporter (like MDMA), leading to both stimulant and emotional modulation effects in laboratory models.

• Unique Pharmacodynamics: While MDMA primarily releases serotonin and MDPV inhibits dopamine/norepinephrine reuptake, MDMAMDPV displays a combination of these actions, which allows researchers to study compound synergy.

• Research Versatility: MDMAMDPV’s hybrid nature enables its use in studies investigating cross-system neurotransmission, interaction models, and potential tolerance patterns across different stimulant types.

• Duration & Potency Differences: MDMAMDPV has a moderate onset and duration (4–6 hours), which places it between MDMA’s more emotional peak and MDPV’s intense and often prolonged stimulation.

• Not Recreationally Used: While some compounds cross into recreational misuse, MDMAMDPV is not widely known outside research circles and lacks the human trial documentation associated with MDMA.

MDMAMDPV holds particular interest in scientific studies that explore the behavioral, neurochemical, and metabolic implications of compounds affecting multiple monoamine systems. It is useful in both academic and forensic research contexts where novel hybrid stimulants and empathogens are under investigation.

• Neurotransmitter Transporter Studies: Due to its dual interaction with serotonin and dopamine transporters, MDMAMDPV allows researchers to study simultaneous transporter inhibition effects and evaluate neurotransmitter release modulation.

• Behavioral Toxicology: MDMAMDPV is often used in rodent and in vitro studies to evaluate locomotor activity, anxiety profiles, reward reinforcement behavior, and stimulant/empathogen balance.

• Structure-Activity Relationship (SAR) Analysis: Its structural blend allows comparison with other cathinones and phenethylamines to determine how minor chemical modifications influence pharmacology.

• Forensic Identification Training: MDMAMDPV can be used in controlled environments to train forensic analysts in identifying novel psychoactive substances and analog compounds.

• Metabolite Mapping: The compound is suitable for advanced analytical chemistry applications such as mass spectrometry to explore how MDMAMDPV breaks down and interacts with metabolic enzymes.

• Cross-Tolerance Investigations: Research into whether repeated exposure affects sensitivity to traditional stimulants or MDMA-type drugs can be conducted using this compound.

• Analytical Reference Standard Development: MDMAMDPV can assist in creating reference materials for laboratory libraries or customs analysis.

The legality of MDMAMDPV depends on the regulatory framework of the country or region where the purchase and use take place. As a novel compound, it is often not explicitly scheduled, but analog or blanket bans may apply. At RC Plug, we only ship to jurisdictions where the sale and possession of such research chemicals are permitted for scientific purposes.

• Not Scheduled in Most Countries: As of now, MDMAMDPV is not specifically listed in the schedules of controlled substances in many countries, which may allow legal purchase for research.

• Subject to Analogue Laws: In places like the United States, the compound could fall under the Federal Analogue Act if it is deemed “substantially similar” to a controlled substance like MDPV.

• Psychoactive Substance Acts: Countries such as the UK have broad laws like the Psychoactive Substances Act 2016, which may restrict MDMAMDPV regardless of chemical classification.

• Research-Only Clause: All legal uses of MDMAMDPV must be confined strictly to scientific research, with no intent for human consumption or therapeutic use.

• RC Plug Compliance: We verify regulatory status before accepting orders and reserve the right to refuse shipment to high-risk jurisdictions.

• Documentation Support: Upon request, we can provide lab reports and chemical data sheets to assist with customs clearance or institutional documentation requirements.

Proper storage of MDMAMDPV is essential to preserve its chemical integrity, prevent contamination, and ensure it remains stable for extended periods. Due to its sensitivity to environmental factors, we recommend adhering strictly to best practices for research chemical storage.

• Cool and Dry Conditions: Store in a temperature-controlled environment, ideally between 15–25°C (59–77°F), away from direct sunlight and heat sources.

• Airtight Containers: Use sealed glass or polypropylene containers to prevent exposure to air, moisture, and other reactive elements.

• Vacuum-Sealing: For long-term storage, vacuum-sealed packaging can enhance stability by minimizing air oxidation and humidity-related degradation.

• Avoid Refrigeration Unless Necessary: Room temperature storage is sufficient in most cases, but low-temperature storage may be used for bulk preservation, avoiding repeated freeze-thaw cycles.

• Labeling: All storage containers should be clearly labeled with the compound name, purity level, batch number, and date of receipt to maintain proper inventory records.

• Keep Away from Volatile Chemicals: MDMAMDPV should be stored separately from acids, oxidizers, and solvents that may affect its composition.

• Child and Unauthorized Access Prevention: Storage should occur in a locked or restricted-access lab environment to ensure safety and legal compliance.

MDMAMDPV is supplied in a crystalline powder form that is highly refined and quality-verified. Its physical appearance can assist in preliminary identification before analytical verification and contributes to its ease of handling in laboratory settings.

• Color and Texture: Usually appears as a white to off-white powder with a smooth, consistent grain. Variations in shade may indicate impurities or degradation.

• Crystalline Granularity: The fine crystal structure allows for precise weighing and solubilization during experimental preparation.

• Odor Profile: May emit a faint chemical odor typical of cathinones, though not strong or irritating under normal handling conditions.

• Moisture Content: A properly stored sample should have minimal moisture absorption. Sticky or clumped textures may suggest improper storage or exposure.

• Homogeneity: Our batches are homogenized to ensure consistency throughout each order, which supports reproducible lab outcomes.

• Visual Inspection Utility: While not a substitute for spectroscopy or chromatography, visual checks offer a quick reference point during setup or verification.

Mixing MDMAMDPV with other research chemicals is a highly specialized practice that must only occur under tightly controlled laboratory protocols. Due to its complex dual action on serotonin and dopamine systems, combining MDMAMDPV with other compounds could result in unpredictable interactions or synergistic effects. Such combinations must be approached cautiously, particularly when studying neurochemical cross-reactions.

• Risk of Serotonin Syndrome in Models: Combining MDMAMDPV with other serotonin-releasing agents (such as 5-HTP, MDMA, or SSRIs) can lead to excessive serotonin activity, which may present toxicological challenges in vitro or in vivo.

• Potentiation with Dopaminergic Compounds: When mixed with dopamine reuptake inhibitors (like α-PVP or cocaine analogues), MDMAMDPV’s stimulant effects may intensify, complicating behavioral analysis and increasing potential cellular stress.

• Receptor Competition: Compounds with overlapping receptor targets may interfere with MDMAMDPV’s activity, making it harder to isolate its specific binding affinities during transporter or receptor assays.

• Altered Pharmacokinetics: Co-administered chemicals may influence absorption, metabolic rate, or excretion of MDMAMDPV in biological test systems, affecting interpretation of results.

• Unpredictable Toxicity: Novel combinations may yield previously unrecorded metabolic byproducts or elevate oxidative stress markers in lab animals or cell cultures.

• Solvent Compatibility: Mixing in the same solution requires that all compounds share solubility in the same medium (e.g., DMSO or ethanol) without causing precipitation or degradation.

• Isolated Testing Preferred: Best practice is to establish a baseline profile of MDMAMDPV on its own before conducting co-administration trials.

Analyzing MDMAMDPV in laboratory settings involves a combination of qualitative and quantitative techniques to verify identity, measure concentration, and determine purity. These methods are crucial for accurate research outcomes and for detecting possible contaminants or structural analogs.

• GC-MS (Gas Chromatography-Mass Spectrometry): This technique is widely used to separate and identify MDMAMDPV based on its molecular fragmentation pattern. GC-MS is ideal for confirming compound identity and detecting impurities in complex mixtures.

• HPLC (High-Performance Liquid Chromatography): Essential for determining compound purity and concentration, HPLC can quantify active ingredients and degradation products with high precision.

• NMR Spectroscopy (Nuclear Magnetic Resonance): NMR provides structural confirmation by mapping the chemical environment of hydrogen and carbon atoms within the compound.

• FTIR (Fourier Transform Infrared Spectroscopy): FTIR detects specific functional groups in MDMAMDPV, making it useful for confirming the presence of methylenedioxy and amine groups.

• UV-Vis Spectroscopy: Absorbance data from ultraviolet and visible light can be used for concentration estimates when analyzing solutions of known molarity.

• Melting Point Testing: Although less specific, the melting point of a sample can serve as a quick check for compound purity and batch consistency.

• Solubility Testing: Researchers often determine which solvents MDMAMDPV dissolves in before setting up experiments, as solubility affects bioavailability in biological models.

Handling MDMAMDPV requires strict adherence to chemical safety protocols. As a potent and unregulated compound, MDMAMDPV must only be manipulated in certified lab environments by trained professionals using appropriate equipment and procedures.

• Personal Protective Equipment (PPE): Always wear gloves, lab coat, and safety goggles to prevent skin and eye contact. A dust mask or respirator is recommended if handling powder in open air.

• Fume Hood Use: Conduct all weighing, transferring, or solution preparation inside a certified chemical fume hood to prevent inhalation of airborne particles.

• Avoid Skin and Mucous Contact: Even trace amounts can pose risk through absorption or accidental ingestion. Always wash hands thoroughly after use.

• Dedicated Tools: Use designated spatulas, containers, and balances to avoid cross-contamination with other chemicals or test compounds.

• No Food or Drink: Never eat, drink, or store consumables in areas where MDMAMDPV is used or stored.

• Proper Waste Disposal: Dispose of unused samples and contaminated equipment through approved chemical waste channels, following institutional or regional safety regulations.

• Material Safety Data Sheet (MSDS): Keep the MSDS for MDMAMDPV readily accessible and ensure all lab staff are familiar with emergency protocols.

Solubility plays a vital role in how MDMAMDPV can be used in laboratory experiments. It affects delivery methods, compatibility with analytical techniques, and the reliability of quantitative assessments. Understanding solvent compatibility is key to safe and effective handling.

• Ethanol and Methanol: MDMAMDPV is readily soluble in both ethanol and methanol, making these common solvents for preparing standard solutions in HPLC or UV-Vis analysis.

• DMSO (Dimethyl Sulfoxide): Excellent solvent for achieving high concentrations of MDMAMDPV. DMSO is frequently used in biological assays due to its low toxicity in small quantities.

• Acetonitrile: Solubility in acetonitrile is moderate and can be suitable for LC-MS applications or as part of a solvent gradient system.

• Chloroform and Dichloromethane: May dissolve MDMAMDPV but are generally avoided in biological systems due to their high toxicity and volatility.

• Water: MDMAMDPV is poorly soluble in water due to its hydrophobic molecular structure, making aqueous solutions impractical for most experiments.

• Buffered Solutions: May allow partial solubility when mixed with ethanol or DMSO in low concentrations; useful for cell culture models requiring isotonic conditions.

• Precipitation Risk: Solubility thresholds should always be tested in small volumes before large-scale preparation to avoid unexpected crystallization.

Although the exact synthesis of MDMAMDPV is not disclosed for safety and legal reasons, it is understood to involve principles used in the creation of substituted cathinones and phenethylamines. The synthesis should only be conducted in licensed research laboratories equipped to handle advanced organic synthesis protocols.

• Alpha-Carbon Substitution: The synthetic route likely begins with the modification of a pentanone skeleton to introduce a methylamino group at the alpha position.

• Benzodioxole Ring Attachment: A methylenedioxyphenyl moiety is typically introduced via a substituted benzaldehyde intermediate, a step common in MDMA synthesis.

• Reductive Amination: The final amine may be introduced through a reductive amination process, forming the methylamino group bonded to the alkyl chain.

• Pyrrolidine Analogue Variation: Some synthetic pathways may explore analogs using pyrrolidine ring substitutions, though MDMAMDPV retains a simpler alkyl structure.

• Reagent Sensitivity: The process may involve controlled reagents such as reducing agents (e.g., sodium borohydride) and organic catalysts, requiring expert handling.

• Analytical Verification: Each step must be verified through analytical tools like NMR and MS to ensure compound identity and purity.

• Not Suitable for Unlicensed Production: All synthesis must be conducted under strict legal and ethical guidelines. Unauthorized synthesis is illegal and hazardous.

In laboratory and preclinical settings, MDMAMDPV demonstrates a unique combination of effects due to its dual action on the dopamine and serotonin systems. While not tested in humans, controlled animal studies and in vitro data suggest that MDMAMDPV produces both stimulant and entactogenic responses, making it an important compound for understanding hybrid neurochemical dynamics.

• Increased Locomotor Activity: Rodent studies often report heightened physical activity after administration, indicating strong dopaminergic stimulation.

• Empathogenic Behavioral Markers: Research suggests an increase in social interaction or prosocial behaviors in lab animals, which is consistent with serotonergic engagement.

• Elevated Reward Sensitivity: Conditioned place preference experiments may show a preference for MDMAMDPV-associated environments, supporting its reinforcing properties.

• Heart Rate and Blood Pressure Elevation: Although measured indirectly in animal models, MDMAMDPV has shown sympathomimetic activity associated with cathinones.

• Mixed Neurotransmitter Release: In vitro data indicates significant release or reuptake inhibition of serotonin, dopamine, and possibly norepinephrine.

• Delayed Onset Compared to Pure Stimulants: The presence of entactogenic effects can modulate the pacing and intensity of stimulation, providing a longer, more balanced response profile.

• Dose-Dependent Variability: Low doses may produce subtle emotional effects, while higher doses favor intense stimulation and potential neurochemical stress.

Neurotoxicity is a critical concern when studying synthetic cathinones and phenethylamines. MDMAMDPV has not undergone extensive neurotoxicity profiling, but based on its pharmacological relatives, there is potential for neuronal damage at high concentrations or prolonged exposure. Researchers must exercise caution when studying its effects on cellular or neural systems.

• Oxidative Stress Generation: Like MDMA and MDPV, MDMAMDPV may increase reactive oxygen species (ROS) production, particularly in serotonergic neurons.

• Transporter Overload: Repeated or high-dose activation of monoamine transporters can lead to transporter dysfunction and downstream neurotoxicity.

• Serotonin Receptor Overstimulation: Excessive serotonin activity is linked to neurodegeneration in certain brain regions, especially if antioxidant defenses are compromised.

• Mitochondrial Disruption: Preliminary studies suggest compounds in this class can impair mitochondrial function, leading to cell death via energy depletion.

• Dopaminergic Toxicity: Dopaminergic neurons are especially vulnerable to oxidative byproducts of dopamine metabolism, increasing the risk of neuronal stress.

• Microglial Activation: MDMAMDPV may indirectly promote neuroinflammation via glial cell activation, which contributes to long-term damage.

• Dose-Dependent Risks: Neurotoxic potential increases sharply with dosage and exposure time. Lower, short-duration exposure in vitro is generally safer for controlled experiments.

MDMAMDPV demonstrates a relatively rapid onset and moderate duration of activity when tested in research environments. Its pharmacokinetic profile appears to blend characteristics of both fast-acting stimulants and longer-lasting empathogens, making it valuable for time-course studies in neurobehavioral pharmacology.

• Onset of Action: Lab observations suggest MDMAMDPV begins to exert measurable effects within 15–30 minutes of administration in animal models or test solutions.

• Peak Effects: The compound generally reaches peak activity at around 1 to 2 hours post-application, depending on the administration method and solvent.

• Total Duration: Effects tend to last between 4 to 6 hours, with gradual tapering of neurochemical changes afterward.

• Residual Impact: Low-level alterations in neurotransmitter balance or behavioral inhibition may persist beyond the primary active window.

• Influence of Dose and Solvent: Higher doses or lipid-soluble solvents can accelerate onset and prolong effect duration by affecting absorption rates.

• CNS Penetration: MDMAMDPV’s structure suggests effective blood-brain barrier permeability, which contributes to its rapid central nervous system action.

• Ideal for Mid-Duration Assays: Its moderate time window makes it useful for multi-phase experimental designs where both acute and post-exposure behaviors are monitored.

No. MDMAMDPV is not approved for human consumption under any circumstances. It is classified strictly as a research chemical and is intended solely for in vitro analysis, animal studies, or chemical assay development. Human exposure poses unpredictable risks and violates ethical and legal research standards.

• No Clinical Trials or Toxicology Data: MDMAMDPV has not undergone human testing or regulatory review, so its pharmacokinetics, side effects, and toxicity in humans remain unknown.

• High Risk of Adverse Reactions: Based on its stimulant and serotonergic profile, uncontrolled exposure could result in dangerous physiological responses like seizures, cardiovascular stress, or serotonin syndrome.

• Legal Consequences: Human use may constitute a violation of analog laws or health regulations, potentially leading to prosecution or research sanctions.

• Lack of Antidote or Standard Protocols: In the event of accidental ingestion or exposure, there are no standardized treatment procedures or antidotes.

• Ethical Restrictions: Reputable research institutions prohibit human trials involving unscheduled chemicals without prior approval from ethics committees or regulatory boards.

• Liability Issues: Personal or institutional liability can arise from unauthorized use outside a controlled lab setting.

• RC Plug Policy: We provide MDMAMDPV exclusively for licensed research use, and any other application is explicitly prohibited.

MDMAMDPV exerts its primary effects through indirect interactions with serotonin and dopamine systems, primarily by inhibiting the reuptake of these neurotransmitters via their respective transporters. While not a direct receptor agonist, it significantly alters neurotransmission patterns, influencing receptor activity downstream.

• Serotonin Transporter Inhibition (SERT): MDMAMDPV likely inhibits SERT, increasing extracellular serotonin levels and triggering downstream serotonergic receptor activation.

• Dopamine Transporter Inhibition (DAT): Strong inhibition of DAT results in elevated synaptic dopamine, which is associated with stimulant and reinforcing effects.

• Norepinephrine Transporter Inhibition (NET): Some evidence suggests partial NET inhibition, which may contribute to increased alertness, heart rate, and blood pressure in test subjects.

• No Direct Agonism: MDMAMDPV does not bind directly to serotonin or dopamine receptors in most assays, but it modulates receptor activity via neurotransmitter overflow.

• Receptor Desensitization Risk: Prolonged exposure may lead to downregulation or desensitization of key receptors such as 5-HT2A or D2, affecting future neurotransmission.

• Neurochemical Feedback Loops: The indirect stimulation of receptors can alter feedback systems in the brain, such as those involved in mood regulation or behavioral reinforcement.

• Comparable to MDMA Mechanism: Its interaction pattern resembles that of MDMA, though with a more balanced stimulant profile due to MDPV-like dopaminergic emphasis.